Loxo Oncology Announces Plans for LOXO-101
In a recent press release, Loxo Oncology announced an update on the status of their TRK (tropomyosin receptor kinase) inhibitor drug, larotrectinib (LOXO-101). Larotrectinib targets the NTRK genes, which encode for the TRK kinases. [...]